Luca Sigalotti
Overview
Explore the profile of Luca Sigalotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montico B, Giurato G, Guerrieri R, Colizzi F, Salvati A, Nassa G, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):53.
PMID: 39953610
Background: About 50% of cutaneous melanoma (CM) harbors the activating BRAF mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number...
2.
Sigalotti L, Frezza A, Sbaraglia M, Del Savio E, Baldazzi D, Valenti B, et al.
Mod Pathol
. 2024 Nov;
38(1):100647.
PMID: 39491746
Epithelioid sarcoma (ES) is a rare tumor hallmarked by the loss of INI1/SMARCB1 expression. Apart from this alteration, little is known about the biology of ES. Despite recent advances in...
3.
Muraro E, Montico B, Lum B, Colizzi F, Giurato G, Salvati A, et al.
Front Immunol
. 2024 Mar;
15:1336566.
PMID: 38510242
Introduction: About 50% of cutaneous melanoma (CM) patients present activating BRAF mutations that can be effectively targeted by BRAF inhibitors (BRAFi). However, 20% of CM patients exhibit intrinsic drug resistance...
4.
Casarotto M, Lupato V, Giurato G, Guerrieri R, Sulfaro S, Salvati A, et al.
Clin Epigenetics
. 2022 Dec;
14(1):171.
PMID: 36503584
Background And Purpose: Currently, human papillomavirus (HPV) positivity represents a strong prognostic factor for both reduced risk of relapse and improved survival in patients with oropharyngeal squamous cell carcinoma (OPSCC)....
5.
Montico B, Giurato G, Pecoraro G, Salvati A, Covre A, Colizzi F, et al.
Mol Oncol
. 2021 Jun;
16(3):565-593.
PMID: 34080276
Cutaneous melanoma (CM) is a very aggressive disease, often characterized by unresponsiveness to conventional therapies and high mortality rates worldwide. The identification of the activating BRAF mutations in approximately 50%...
6.
Montico B, Colizzi F, Giurato G, Rizzo A, Salvati A, Baboci L, et al.
Cell Death Dis
. 2020 May;
11(5):392.
PMID: 32444628
Mitogen-activated protein kinase (MAPK) pathway activation is a central step in BRAF-mutant cutaneous melanoma (CM) pathogenesis. In the last years, Spry1 has been frequently described as an upstream regulator of...
7.
Di Giacomo A, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7351-7362.
PMID: 31530631
Purpose: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies. The phase Ib NIBIT-M4 trial tested this hypothesis using the next-generation DHA...
8.
Sigalotti L, Covre A, Colizzi F, Fratta E
Methods Mol Biol
. 2018 Dec;
1909:137-162.
PMID: 30580429
Aberrant DNA methylation of cell-free circulating DNA (cfDNA) has recently gained attention for its use as biomarker in cancer diagnosis, prognosis, and prediction of therapeutic response. Quantification of cfDNA methylation...
9.
Furlan C, Polesel J, Barzan L, Franchin G, Sulfaro S, Romeo S, et al.
Clin Epigenetics
. 2017 Jun;
9:58.
PMID: 28572862
Background: Inclusion of new biomarkers to improve a personalized treatment approach for oropharyngeal squamous cell carcinoma (OPSCC) is urgently needed. Hypomethylation of the Long interspersed nucleotide element-1 (LINE-1) repetitive elements,...
10.
Fratta E, Montico B, Rizzo A, Colizzi F, Sigalotti L, Dolcetti R
Oncotarget
. 2016 Jun;
7(35):57327-57350.
PMID: 27329599
In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators...